Biohaven Ltd.
NYSE:BHVNBiotechnology
-$0.22 today
- Market cap
- $1.95B
- Beta
- 3.31
- P/E (TTM)
- -3.1
- EPS (TTM)
- -$4.39
Volume 2.32M
Average 2.47M
BHVN EPS (Basic)
Net income attributable to common shareholders divided by the weighted average basic shares outstanding.
Biohaven Ltd.NYSE: BHVN
EPS (Basic) · Q2 FY2026 · quarter ended Jun 2026
EPS (Basic) remains negative
Q2 FY2026 EPS (Basic) was -$0.91, compared with -$1.94 a year earlier. Trailing-twelve-month EPS (Basic) was -$4.64.
Context
- EPS (Basic) grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EPS (Basic) reaches the consensus estimate from 11 analysts of -$2.99 (+56.4%) for the fiscal year ending Dec 2026, a step up from the +26.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$0.91-3.4% QoQ
- Last fiscal yearDec 2025
- -$6.86+26.1% YoY
- LTMJun 2026
- -$4.64+39.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +53.1% | +55.8% | +2.7 pp |
| 1 year | +26.1% | +56.4% | +30.3 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Basic) history
USD · from the income statement
- Latest · FY2025
- (6.86) USD
- Year-over-year change
- +26.1%
| Period | Period end | EPS (Basic) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (6.86) | +26.1% |
| FY2024 | 2024-12-31 | (9.28) | -62.0% |
| FY2023 | 2023-12-31 | (5.73) | +55.1% |
| FY2022 | 2022-12-31 | (12.75) | -113.6% |
| FY2021 | 2021-12-31 | (5.97) | — |
EPS (Basic) vs competitors
How BHVN compares with its peers on the latest reported figures
- Peers report in different currencies, so EPS (Basic) is compared through growth and rates rather than absolute size.
- Its year-over-year change of +39.4% is the 2nd highest of 11, against a peer median of +7.7%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $0.07 USD | +123.2% | — | |
| LTM Mar 2026 | -$0.37 USD | +12.9% | — | |
| LTM Sep 2026 | -$0.48 USD | +17.2% | — | |
| LTM Mar 2026 | -$1.93 USD | -28.1% | — | |
| LTM Sep 2026 | -$2.65 USD | +10.2% | — | |
| LTM Sep 2026 | -€2.77 EUR | +5.1% | — | |
| LTM Mar 2026 | -$3.54 USD | +32.3% | — | |
| LTM Sep 2026 | -$4.31 USD | -27.5% | — | |
| LTM Jun 2026 | -$4.64 USD | +39.4% | — | |
| LTM Jun 2026 | -$5.86 USD | -58.0% | — | |
| LTM Mar 2026 | -$9.1 USD | -129.2% | — | |
| Peer median (excluding BHVN) | — | +7.7% | — | |
Competitors are the stored peer set for BHVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 4.14M |
| Gross Profit | 0 | 0 | 0 | 0 | (4.14M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 181.49M | 437.07M | 373.28M | 795.87M | 635.07M |
| Selling, General & Admin | 37.41M | 130.86M | 62.77M | 89.24M | 106.17M |
| Operating Expenses | 218.9M | 567.93M | 436.05M | 885.11M | 741.24M |
| Depreciation & Amortization | 1.39M | 1.39M | 6.91M | 7.86M | 9.92M |
| EBITDA | (211.04M) | (568.46M) | (402.64M) | (837.83M) | (727.46M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (218.9M) | (567.93M) | (436.05M) | (885.11M) | (745.38M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 17.73M | 21.33M | 14.59M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 6.47M | (1.91M) | 26.5M | 39.42M | 8M |
| Income Before Tax | (212.43M) | (569.84M) | (409.55M) | (845.69M) | (737.38M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 1.37M | 438K | (1.38M) | 735K | 1.44M |
| Net Income | (213.8M) | (570.28M) | (408.17M) | (846.42M) | (738.82M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (5.97) | (12.75) | (5.73) | (9.28) | (6.86) |
| EPS (Diluted) | (5.97) | (12.75) | (5.73) | (9.28) | (6.86) |
| Weighted Avg Shares | 35.82M | 44.74M | 71.2M | 91.23M | 107.62M |
| Weighted Avg Shares (Diluted) | 35.82M | 44.74M | 71.2M | 91.23M | 107.62M |
Biohaven Ltd.
NYSE:BHVN
Intrinsic Alpha fair value
Locked
Current Price
$12.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.